COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Department of Health and Human Services today released its strategy for the public distribution of a COVID-19 vaccine.
The Food and Drug Administration released comparative performance data for 55 COVID-19 molecular diagnostic tests.
A Centers for Disease Control and Prevention study revealed that adults with positive SARS-CoV-2 test results were approximately twice as likely to have reported dining at restaurants within 14 days of developing symptoms compared with those whose test results were negative.
A new Centers for Disease Control and Prevention study is revealing the extent to which adults are bypassing medical care because of their COVID-19-related concerns.
The Centers for Disease Control and Prevention Sept. 17 at 2 p.m. ET will host a Clinician Outreach and Communication Activity webinar on using antivirals to treat influenza and whether the U.S. could see fewer cases, as indicated by data from the Southern Hemisphere’s 2020 flu season.
The Centers for Medicare & Medicaid Services (CMS) recently issued new surveyor guidance for COVID-19 laboratory test result reporting for Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories.
The Centers for Medicare & Medicaid Services issued new surveyor guidance for COVID-19 laboratory test result reporting for Clinical Laboratory Improvement Amendments-certified laboratories.
AHA urges the Centers for Medicare & Medicaid Services (CMS) to withdraw the condition of participation that hospitals report daily COVID-19 data.
The Food and Drug Administration further expanded the authorized use of remdesivir for treating COVID-19 patients, the agency announced. Now, remdesivir can be used for all admitted COVID-19 patients, confirmed or suspected, whether on oxygen, off oxygen or intubated.